Previous
Previous

CLSP-1025, a first-in-class precision T-cell engager for the treatment of p53 mutant cancers

Next
Next

Clasp Therapeutics Presents Comprehensive Preclinical Data Validating First-in-Class Precision T Cell Engager Against p53 Mutant Solid Tumors at SITC Annual Meeting